TABLE 2.
Prone positioning group | Control group | |
Subjects, n | 29 | 32 |
Clinically relevant adverse events | ||
Thromboembolic event | 2 (6.9) | 3 (9.4) |
Gastrointestinal bleeding | 0 | 1 (3.1) |
Cardiovascular events | 2 (6.9) | 1 (3.1) |
Infection | 3 (10.3) | 4 (12.5) |
Grade ≥3 adverse events # | 4 (13.8) | 6 (18.7) |
Data are presented as n (%), unless otherwise indicated. #: severity scale: 1=mild, 2=moderate, 3=serious, 4=life-threatening, 5=fatal.